Introduction: Psoriasis is a global burden of disease characterized by the presence of well circumscribed erythematous papule & plaque of various size & shape, covered by silvery scales. It not only hampers the quality of life but also hampers the sexual function. Men who have psoriasis may be more likely to have sexual problems, such as sexual apathy, orgasmic dysfunction, erectile dysfunction (ED), etc. Stress tends to be a triggering or aggravating factor in psoriasis. In addition, the disease itself can generate emotional stress because of its lesions. It is thought that chronic inflammation. Results in metabolic diseases and proinflammatory cytokines give rise to the development of atherogenesis. Pelvic arterial atherosclerosis is another cause of sexual dysfunction. This study was designed to determine the impact of moderate to severe psoriasis on quality of life and sexual dysfunction in male patients. Methods: This case control study was conducted in Department of Dermatology and Venereology, Dhaka Medical College Hospital, among the 100 patients. Group- A was cases (male married patients age between 24 years and 60 years with history of moderate to severe psoriasis) and group-B were control (male married patients age between 24 years and 60 years without psoriasis). Then variables were analyzed and compared. Data was processed and analyzed with the help of computer program SPSS and Microsoft excel. Quantitative data expressed as mean and standard deviation and qualitative data as frequency and percentage. Comparison was done by tabulation and graphical presentation in the form of tables, pie chart, graphs, bar diagrams, histogram & charts etc. Results: It was found that majority of the patients i.e. 46% were between 34-43 years, mean age was found to 41.7±11.3 years. No significant difference in age and other demographic profile was observed between groups. Prevalence of IHD (8.0%), stroke (14.0%), dyslipidaemia (54.0%), neuropathy (26.0%) and PVD (8.0%) were higher in case or psoriatic patients. On evaluation of Dermatology Life Quality Index (DLQI), majority of patients (54%) score was 6-10, followed by 24.0% had score 2-5 and 22.0% of patients had score 11-20 or very large effect on patient’s life. Prevalence of erectile dysfunction was 36.0%, prevalence of orgasmic dysfunction was 24.0%. On multivariate analysis which was done by ordinal logistic regression procedure. The attributes found to be positively associated with sexual dysfunction severity in the multivariate model were patient’s age, disable status, sedentary work, duration of illness, etc. Conclusion: Erectile dysfunction and orgasmic dysfunction are common in psoriatic male patients. There is association with other comorbidities. J Bangladesh Coll Phys Surg 2022; 40: 233-228
Background: Androgenetic alopecia (AGA) also known as male pattern baldness is the most common hair loss disorder characterized by chronic, nonscarring disorder that is marked by a progressive reduction in the diameter, length, and pigmentation of the hair. This disorder is located primarily on the central scalp with various patterns of loss. Pathophysiological features include an alteration in the hair cycle via reduction of the anagen (growth) phase, inflammation, and follicular miniaturization. Therapies for AGA are limited and there is no cure. There is a high demand for hair restoration. Platelet-rich plasma (PRP), a treatment modality shown to promote wound healing, has also been explored as a treatment for AGA. Objectives: To observe the effectiveness of platelet-rich plasma for Androgenetic Alopecia. Materials & method: This prospective observational study was conducted among 30 subjects with androgenetic alopecia from July 2018 to June 2020 in a reputed private hospital in Dhaka. Five platelet-rich plasma (PRP) treatments, at intervals of 4 –5 weeks, and 2 follow-up examinations were performed. Blood (9 cc) from each AGA patient was collected in 10 cc syringe, and PRP was isolated using commercially available kit under sterilized conditions. Isolated PRP was injected in the bald areas of scalp of AGA patients. Treatment efficacy was assessed by changes in hair number and diameter. A secondary objective was to assess clinical improvement, which was evaluated by 5-point Likert scale. Then variables were analyzed and compared. Data was processed and analysed with the help of computer program SPSS and Microsoft excel. Quantitative data expressed as mean and standard deviation and qualitative data as frequency and percentage. Comparison was done by tabulation and graphical presentation in the form of tables, pie chart, graphs, bar diagrams, histogram & charts etc. Result: It was found that majority of the patients i.e. 41(68.3%) were in the age group 20-40 years, mean age was found to 38.3±6.5 years. No significant difference in age and other demographic profile was observed between groups. The median (range) hair number per square centimetre at baseline was 38.0 (13-105) in the both groups. At the final follow-up visit, hair number is improved & it was found 53.0 (24-130) in the treated group and 41.0 (11-105) in the control group. Differences was statistically significant (p=0.017). Hair diameter (μm) at baseline was 65.0 (48-81) μm in the treated group and 66.0 (49-75) in the control group. At the final follow up visit, hair diameter also improved and it was 80.0 (58-94) μm in the treated group and 69.0 (51-85) μm in the control group. Differences was statistically significant (p=0.031). There were no treatment-related adverse effects. Conclusion: Present study concluded that PRP is an effective treatment option in androgenetic alopecia, provides better clinical outcome in terms of improve hair density, diameter and significant subject satisfaction. J Shaheed Suhrawardy Med Coll 2021; 13(2): 158-163
Background: COVID-19 is the pandemic disease causes severe acute respiratory infection. Tcell mediated responses are activated and responses are initiated by antigen presentation via DCs and macrophages. Immunologically SARS-CoV showed that virus infected lung epithelial cells produced IL-8 in addition to IL-6. A hyperinflammatory environment has been a hallmark of COVID 19 infection and is thought to be a key mediator of morbidity and mortality. C-reactive protein (CRP), an inflammatory marker, can be used in the diagnosis of COVID pneumonia. Purpose: To find out the role of CRP in COVID-19 Infection and comparison with Chest Computed Tomography. Materials and method: This cross sectional prospective study was conducted in Department of Medicine, Dhaka Medical College Hospital, among the 100 patients with symptomatic and positive RT-PCR for SARS-CoV-2. C-reactive protein (CRP) level was compared with HRCT findings. All the information collected in data collection sheet and analyzed using SPSS version-22. Result: Mean age of the patient was 45.2 ± 8.5 years. Fever and cough was commonest presentation, 79.0% and 36.0% of patients respectively. It showed, 27.0% cases were found to have raised CRP where 73.0% had normal level with mean value 14.1 mg/L. Chest HRCT imaging finding revealed, 44% patients had 26–50% lung involvement and 16 patients had 51–75% involvement. In maximum patients (57.0%), chest CT showed single or multiple GGO. HRCT score was significantly higher in patients with raised CRP, and a significant positive significant correlation (r=0.941; p=0.001) between the HRCT scores and CRP level. Conclusion: The rising CRP can aid in predicting COVID-19 pneumonia and significantly correlates with percentage of lung involvement on HRCT in COVID-19 pneumonia. J Dhaka Med Coll. 2021; 30(2) : 136-141
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.